Medpace Faces Class Action Lawsuit Allegations
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Apr 21 2026
0mins
Should l Buy MEDP?
Source: PRnewswire
- Class Action Initiation: Robbins Geller Rudman & Dowd LLP announces that investors who purchased Medpace Holdings Inc. (NASDAQ:MEDP) stock between April 22, 2025, and February 9, 2026, can seek lead plaintiff status by June 8, 2026, indicating strong investor concern over the company's financial transparency.
- Financial Misconduct Allegations: The lawsuit alleges that Medpace and its executives violated the Securities Exchange Act of 1934 by overstating the projected book-to-bill ratio for Q4 2025, leading to investor misconceptions about the company's performance, which could adversely affect shareholder confidence and market performance.
- Stock Price Volatility: Following the release of Q4 2025 earnings on February 9, 2026, which revealed a book-to-bill ratio of only 1.04, significantly below expectations, Medpace's stock price plummeted nearly 16%, reflecting market disappointment and a crisis of trust in the company.
- Legal Process Overview: Under the Private Securities Litigation Reform Act of 1995, any investor who purchased Medpace stock during the class period can apply to be the lead plaintiff, who will represent other investors in the lawsuit, emphasizing the critical role of investors in legal proceedings.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy MEDP?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on MEDP
Wall Street analysts forecast MEDP stock price to rise
7 Analyst Rating
1 Buy
4 Hold
2 Sell
Hold
Current: 428.710
Low
462.00
Averages
569.17
High
660.00
Current: 428.710
Low
462.00
Averages
569.17
High
660.00
About MEDP
Medpace Holdings, Inc. is a scientifically driven, global, full-service clinical contract research organization (CRO) providing phase I-IV clinical development services to the biotechnology, pharmaceutical and medical device industries. The Company partners with pharmaceutical, biotechnology, and medical device companies in the development and execution of clinical trials. The Company’s drug development services focus on full-service Phase I-IV clinical development services and include development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support. The Company also provides bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials. The Company’s operations are principally based in North America, Europe, and Asia.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Medpace Faces Class Action Lawsuit Allegations
- Class Action Initiation: Robbins Geller law firm announces that investors who purchased Medpace Holdings Inc. (NASDAQ: MEDP) common stock between April 22, 2025, and February 9, 2026, can seek lead plaintiff status by June 8, 2026, highlighting significant investor concern over the company's financial transparency.
- False Statement Allegations: The lawsuit alleges that Medpace and its executives made false or misleading statements during the class period, failing to disclose that their projected book-to-bill ratio for Q4 2025 was overstated, severely undermining investor confidence in the company's performance.
- Performance Decline Impact: On February 9, 2026, Medpace reported a Q4 2025 book-to-bill ratio of 1.04, significantly below the company's guidance of 1.15, causing the stock price to plummet nearly 16%, reflecting market concerns about the company's future growth prospects.
- Legal Process Explanation: Under the Private Securities Litigation Reform Act of 1995, any investor who purchased Medpace stock during the class period can apply to be the lead plaintiff, who will represent other investors in the lawsuit, emphasizing the importance of investor participation in legal proceedings.
See More
Medpace Holdings Faces Class Action Lawsuit Over Securities Violations
- Class Action Filed: Bronstein, Gewirtz & Grossman has initiated a class action lawsuit against Medpace Holdings, alleging violations of federal securities laws from April 22, 2025, to February 9, 2026, seeking damages for affected investors.
- False Statements Allegation: The complaint claims that Medpace misrepresented its expected book-to-bill ratio as approximately 1.15 during earnings calls, despite having contrary internal information, misleading investors about the company's financial health.
- Investor Participation Opportunity: Affected investors have until June 5, 2026, to request appointment as lead plaintiff, allowing them to participate in any recovery without needing to serve as lead plaintiff.
- Law Firm Credentials: Bronstein, Gewirtz & Grossman is recognized for recovering hundreds of millions for investors in securities fraud class actions, underscoring their expertise and commitment to restoring investor capital and corporate accountability.
See More
Medpace Holdings Faces Class Action Lawsuit for Securities Violations
- Class Action Notice: The Schall Law Firm has alerted investors about a class action lawsuit against Medpace Holdings for violations of §§10(b) and 20(a) of the Securities Exchange Act, concerning securities purchased between April 22, 2025, and February 9, 2026, with a deadline for participation set for June 5, 2026.
- False Statements Allegations: The complaint alleges that Medpace made false and misleading statements during the class period, artificially inflating its stock price, which led to investor losses once the truth was revealed, indicating significant misrepresentation in the company's public disclosures.
- Legal Representation Information: Schall Law Firm specializes in securities class actions and offers free consultations to affected investors, urging them to contact the firm before class certification to ensure their rights are protected and avoid being absent class members.
- Market Reaction: The exposure of the lawsuit may undermine investor confidence in Medpace, potentially leading to further stock price volatility, reflecting serious deficiencies in the company's transparency and compliance practices.
See More
Medpace Faces Class Action for Securities Fraud
- Lawsuit Background: Leading securities law firm Bleichmar Fonti & Auld LLP has filed a class action lawsuit against Medpace Holdings Inc. and certain executives, alleging securities fraud due to intentional understatements of cancellation rates and overstatements of the book-to-bill ratio, resulting in a 15.9% stock drop on February 9, 2026.
- Stock Price Volatility: On February 9, 2026, Medpace's stock plummeted from $530.35 to $446.05 per share, reflecting severe investor concerns regarding the company's financial health and negatively impacting market expectations for future performance.
- Misleading Financial Data: Medpace claimed a decrease in cancellation rates in its Q4 2025 report, but the reality was an increase in cancellations, leading to a decline in the book-to-bill ratio to 1.04, which further dropped to 0.88 in Q1 2026, indicating underlying operational risks.
- Executive Changes: Amid ongoing stock declines, Medpace's President Jesse Geiger announced his resignation, potentially exacerbating market unease regarding the company's governance and future development.
See More
Reminder for Medpace Stock Class Action Lawsuit
- Class Action Notice: Rosen Law Firm reminds investors who purchased Medpace Holdings, Inc. (NASDAQ:MEDP) common stock between April 22, 2025, and February 9, 2026, to apply as lead plaintiffs by June 8, 2026, to participate in the class action lawsuit and seek compensation.
- Fee Arrangement: Investors joining the class action will incur no out-of-pocket costs, as the law firm operates on a contingency fee basis, which alleviates financial burdens and encourages more affected investors to participate.
- Lawsuit Background: The lawsuit alleges that Medpace made false or misleading statements during the class period, concealing its true backlog cancellation rates, which led to overly optimistic growth expectations among investors, ultimately resulting in financial losses.
- Law Firm Expertise: Rosen Law Firm specializes in securities class actions and has achieved the largest securities class action settlement against a Chinese company, demonstrating its expertise and success rate in this field, prompting investors to carefully select experienced legal counsel.
See More
Medpace Faces Class Action Lawsuit Allegations
- Class Action Initiation: Robbins Geller law firm announces that investors who purchased Medpace Holdings Inc. (NASDAQ:MEDP) common stock between April 22, 2025, and February 9, 2026, have until June 8, 2026, to seek lead plaintiff status in the class action lawsuit, indicating significant investor concern over potential financial losses.
- False Statement Allegations: The lawsuit alleges that Medpace and its executives made false and misleading statements during the class period, particularly regarding the projected book-to-bill ratio for Q4 2025, leading to investor misjudgment of the company's performance and potentially triggering broader legal and financial repercussions.
- Performance Decline Impact: On February 9, 2026, Medpace reported a book-to-bill ratio of 1.04 for Q4 2025, significantly below the prior guidance of 1.15, resulting in a nearly 16% drop in stock price, reflecting a severe erosion of market confidence in the company's outlook.
- Legal Process Explanation: Under the Private Securities Litigation Reform Act of 1995, any investor who purchased Medpace stock during the class period can apply to be the lead plaintiff, who will represent other investors in the lawsuit, potentially influencing future recovery outcomes.
See More
Medpace Faces Class Action Lawsuit Allegations
- Class Action Initiation: Robbins Geller law firm announces that investors who purchased Medpace Holdings Inc. (NASDAQ: MEDP) common stock between April 22, 2025, and February 9, 2026, can seek lead plaintiff status by June 8, 2026, highlighting significant investor concern over the company's financial transparency.
- False Statement Allegations: The lawsuit alleges that Medpace and its executives made false or misleading statements during the class period, failing to disclose that their projected book-to-bill ratio for Q4 2025 was overstated, severely undermining investor confidence in the company's performance.
- Performance Decline Impact: On February 9, 2026, Medpace reported a Q4 2025 book-to-bill ratio of 1.04, significantly below the company's guidance of 1.15, causing the stock price to plummet nearly 16%, reflecting market concerns about the company's future growth prospects.
- Legal Process Explanation: Under the Private Securities Litigation Reform Act of 1995, any investor who purchased Medpace stock during the class period can apply to be the lead plaintiff, who will represent other investors in the lawsuit, emphasizing the importance of investor participation in legal proceedings.
See More
Medpace Holdings Faces Class Action Lawsuit Over Securities Violations
- Class Action Filed: Bronstein, Gewirtz & Grossman has initiated a class action lawsuit against Medpace Holdings, alleging violations of federal securities laws from April 22, 2025, to February 9, 2026, seeking damages for affected investors.
- False Statements Allegation: The complaint claims that Medpace misrepresented its expected book-to-bill ratio as approximately 1.15 during earnings calls, despite having contrary internal information, misleading investors about the company's financial health.
- Investor Participation Opportunity: Affected investors have until June 5, 2026, to request appointment as lead plaintiff, allowing them to participate in any recovery without needing to serve as lead plaintiff.
- Law Firm Credentials: Bronstein, Gewirtz & Grossman is recognized for recovering hundreds of millions for investors in securities fraud class actions, underscoring their expertise and commitment to restoring investor capital and corporate accountability.
See More
Medpace Holdings Faces Class Action Lawsuit for Securities Violations
- Class Action Notice: The Schall Law Firm has alerted investors about a class action lawsuit against Medpace Holdings for violations of §§10(b) and 20(a) of the Securities Exchange Act, concerning securities purchased between April 22, 2025, and February 9, 2026, with a deadline for participation set for June 5, 2026.
- False Statements Allegations: The complaint alleges that Medpace made false and misleading statements during the class period, artificially inflating its stock price, which led to investor losses once the truth was revealed, indicating significant misrepresentation in the company's public disclosures.
- Legal Representation Information: Schall Law Firm specializes in securities class actions and offers free consultations to affected investors, urging them to contact the firm before class certification to ensure their rights are protected and avoid being absent class members.
- Market Reaction: The exposure of the lawsuit may undermine investor confidence in Medpace, potentially leading to further stock price volatility, reflecting serious deficiencies in the company's transparency and compliance practices.
See More
Medpace Faces Class Action for Securities Fraud
- Lawsuit Background: Leading securities law firm Bleichmar Fonti & Auld LLP has filed a class action lawsuit against Medpace Holdings Inc. and certain executives, alleging securities fraud due to intentional understatements of cancellation rates and overstatements of the book-to-bill ratio, resulting in a 15.9% stock drop on February 9, 2026.
- Stock Price Volatility: On February 9, 2026, Medpace's stock plummeted from $530.35 to $446.05 per share, reflecting severe investor concerns regarding the company's financial health and negatively impacting market expectations for future performance.
- Misleading Financial Data: Medpace claimed a decrease in cancellation rates in its Q4 2025 report, but the reality was an increase in cancellations, leading to a decline in the book-to-bill ratio to 1.04, which further dropped to 0.88 in Q1 2026, indicating underlying operational risks.
- Executive Changes: Amid ongoing stock declines, Medpace's President Jesse Geiger announced his resignation, potentially exacerbating market unease regarding the company's governance and future development.
See More
Reminder for Medpace Stock Class Action Lawsuit
- Class Action Notice: Rosen Law Firm reminds investors who purchased Medpace Holdings, Inc. (NASDAQ:MEDP) common stock between April 22, 2025, and February 9, 2026, to apply as lead plaintiffs by June 8, 2026, to participate in the class action lawsuit and seek compensation.
- Fee Arrangement: Investors joining the class action will incur no out-of-pocket costs, as the law firm operates on a contingency fee basis, which alleviates financial burdens and encourages more affected investors to participate.
- Lawsuit Background: The lawsuit alleges that Medpace made false or misleading statements during the class period, concealing its true backlog cancellation rates, which led to overly optimistic growth expectations among investors, ultimately resulting in financial losses.
- Law Firm Expertise: Rosen Law Firm specializes in securities class actions and has achieved the largest securities class action settlement against a Chinese company, demonstrating its expertise and success rate in this field, prompting investors to carefully select experienced legal counsel.
See More
Medpace Faces Class Action Lawsuit Allegations
- Class Action Initiation: Robbins Geller law firm announces that investors who purchased Medpace Holdings Inc. (NASDAQ:MEDP) common stock between April 22, 2025, and February 9, 2026, have until June 8, 2026, to seek lead plaintiff status in the class action lawsuit, indicating significant investor concern over potential financial losses.
- False Statement Allegations: The lawsuit alleges that Medpace and its executives made false and misleading statements during the class period, particularly regarding the projected book-to-bill ratio for Q4 2025, leading to investor misjudgment of the company's performance and potentially triggering broader legal and financial repercussions.
- Performance Decline Impact: On February 9, 2026, Medpace reported a book-to-bill ratio of 1.04 for Q4 2025, significantly below the prior guidance of 1.15, resulting in a nearly 16% drop in stock price, reflecting a severe erosion of market confidence in the company's outlook.
- Legal Process Explanation: Under the Private Securities Litigation Reform Act of 1995, any investor who purchased Medpace stock during the class period can apply to be the lead plaintiff, who will represent other investors in the lawsuit, potentially influencing future recovery outcomes.
See More
